Stotz Michael, Liegl-Atzwanger Bernadette, Posch Florian, Mrsic Edvin, Thalhammer Michael, Stojakovic Tatjana, Bezan Angelika, Pichler Martin, Gerger Armin, Szkandera Joanna
Division of Clinical Oncology, Department of Medicine, Medical University of Graz, Graz, Austria.
Research Unit Genetic Epidemiology and Pharmacogenetics, Division of Clinical Oncology, Medical University of Graz, Graz, Austria.
PLoS One. 2016 Jul 25;11(7):e0159448. doi: 10.1371/journal.pone.0159448. eCollection 2016.
Inflammatory blood count biomarkers may improve recurrence risk stratification and inform long-term prognosis of cancer patients. Here, we quantify the prognostic impact of blood-based biomarkers on recurrence risk and long-term survival in a large cohort of gastrointestinal stroma tumor (GIST) patients after curative surgery.
One-hundred-forty-nine consecutive GIST patients were followed-up for a median period of 4.8 years. Local recurrence, distant metastasis, and death occurred in 9, 21, and 31 patients, respectively. Time-to-event and competing risk analysis were applied to study the association between haemoglobin (Hb) level, white blood cell count (WBC), neutrophil/lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte/monocyte ratio (LMR), and platelet/lymphocyte ratio (PLR) with risk of local or distant recurrence (RR), recurrence free survival (RFS), and overall survival (OS).
A low Hb (p = 0.029), and elevations in the parameters WBC (p = 0.004), NLR (p = 0.015) and dNLR (p = 0.037) were associated with a poor OS in GIST patients in multivariate analysis. Moreover, a low Hb (p = 0.049) and an elevated WBC (p = 0.001), NLR (p = 0.007), dNLR (p = 0.043) and PLR (p = 0.024) were independently associated with decreased RFS after adjusting for Miettinen score. However, only an increase of dNLR/NLR showed a significant association to higher RR (p = 0.048). Inclusion of NLR or PLR to Miettinen risk score did not reasonably improve the clinical risk prediction of 2-year RFS.
Low Hb, elevated WBC, elevated dNLR, and elevated PLR are independent prognostic factors for a worse clinical outcome in GIST patients after curative resection.
炎症血细胞生物标志物可能改善癌症患者的复发风险分层并为其长期预后提供依据。在此,我们在一大群接受根治性手术后的胃肠道间质瘤(GIST)患者中,量化基于血液的生物标志物对复发风险和长期生存的预后影响。
对149例连续的GIST患者进行了中位时间为4.8年的随访。分别有9例、21例和31例患者发生局部复发、远处转移和死亡。应用事件发生时间和竞争风险分析来研究血红蛋白(Hb)水平、白细胞计数(WBC)、中性粒细胞/淋巴细胞比值(NLR)、衍生NLR(dNLR)、淋巴细胞/单核细胞比值(LMR)和血小板/淋巴细胞比值(PLR)与局部或远处复发风险(RR)、无复发生存期(RFS)和总生存期(OS)之间的关联。
在多变量分析中,低Hb(p = 0.029)以及WBC(p = 0.004)、NLR(p = 0.015)和dNLR(p = 0.037)参数升高与GIST患者的不良OS相关。此外,在调整Miettinen评分后,低Hb(p = 0.049)以及升高的WBC(p = 0.001)、NLR(p = 0.007)、dNLR(p = 0.分043)和PLR(p = 0.02分4)与RFS降低独立相关。然而,只有dNLR/NLR升高与较高的RR显著相关(p = 0.048)。将NLR或PLR纳入Miettinen风险评分并不能合理改善2年RFS的临床风险预测。
低Hb、升高的WBC、升高的dNLR和升高的PLR是GIST患者根治性切除术后临床结局较差的独立预后因素。